It's hard to know as the stopped phase III trial was placebo controlled not against bisphosphonate as an active comparator plus long term safety is not clear: "The DMC noted that safety issues remain in certain selected areas and made recommendations with respect to following up on them".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.